ArticleCell reports2021
Robust innate responses to SARS-CoV-2 in children resolve faster than in adults without compromising adaptive immunity.
Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 92 citations in OpenAlex.
- Review
- Comparative analysis of adaptive immunity to SARS-CoV-2 in infected children and adults.Pediatric research · 2026Article
- Epidemiological analysis of respiratory pathogen detection in 11 regions of Yunnan from 2021 to 2023.Frontiers in public health · 2026Article
- Article
- Tracing the evolutionary pathway of SARS-CoV-2 through RNA sequencing analysis.Scientific reports · 2025Article
- Age dependent susceptibility and immune responses to La Crosse virus infection in non-human primates.Scientific reports · 2025Article
- Age-associated differences in mucosal and systemic host responses to SARS-CoV-2 infection.Nature communications · 2025Article
- What goes up must come down: dynamics of type 1 interferon signaling across the lifespan.Frontiers in immunology · 2025Review
- Cross-talk between aging resilience pathways and autoimmunity onset.Frontiers in immunology · 2025Review
- The underlying mechanism behind the different outcomes of COVID-19 in children and adults.Frontiers in immunology · 2025Review
- Kinetics and Durability of Antibody and T-Cell Responses to SARS-CoV-2 in Children.The Journal of infectious diseases · 2024Article
- Innate immune signatures in the nasopharynx after SARS-CoV-2 infection and links with the clinical outcome of COVID-19 in Omicron-dominant period.Cellular and molecular life sciences : CMLS · 2024Article
- A T-Cell-Derived 3-Gene Signature Distinguishes SARS-CoV-2 from Common Respiratory Viruses.Viruses · 2024Article
- Harnessing the power of IFN for therapeutic approaches to COVID-19.Journal of virology · 2024Review
- Age-specific nasal epithelial responses to SARS-CoV-2 infection.Nature microbiology · 2024Article
- Diverging patterns in innate immunity against respiratory viruses during a lifetime: lessons from the young and the old.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Comparisons of Pediatric and Adult SARS-CoV-2-Specific Antibodies up to 6 Months after Infection, Vaccination, or Hybrid Immunity.Journal of the Pediatric Infectious Diseases Society · 2024Article
- Early immune profiling reveals distinct inflammatory responses between children and adults few days after primary SARS-CoV-2 infection.Frontiers in immunology · 2024Article
- Variant-specific antibody profiling for tracking SARS-CoV-2 variant infections in children and adolescents.Frontiers in immunology · 2024Article
- New insights into the pathogenesis of SARS-CoV-2 during and after the COVID-19 pandemic.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 4 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 infection in children is less severe than it is in adults. We perform a longitudinal analysis of the early innate responses in children and adults with mild infection within household clusters. Children display fewer symptoms than adults do, despite similar initial viral load, and mount a robust anti-viral immune signature typical of the SARS-CoV-2 infection and characterized by early interferon gene responses; increases in cytokines, such as CXCL10 and GM-CSF; and changes in blood cell numbers. When compared with adults, the antiviral response resolves faster (within a week of symptoms), monocytes and dendritic cells are more transiently activated, and genes associated with B cell activation appear earlier in children. Nonetheless, these differences do not have major effects on the quality of SARS-CoV-2-specific antibody responses. Our findings reveal that better early control of inflammation as observed in children may be key for rapidly controlling infection and limiting the disease course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.